FRANCISCO CARLOS DA COSTA DARRIEUX
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
13 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 13
- European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?(2018) DAGRES, Nikolaos; CHAO, Tze-Fan; FENELON, Guilherme; AGUINAGA, Luis; BENHAYON, Daniel; BENJAMIN, Emelia J.; BUNCH, T. Jared; CHEN, Lin Yee; CHEN, Shih-Ann; DARRIEUX, Francisco; PAOLA, Angelo de; FAUCHIER, Laurent; GOETTE, Andreas; KALMAN, Jonathan; KALRA, Lalit; KIM, Young-Hoon; LANE, Deirdre A.; LIP, Gregory Y. H.; LUBITZ, Steven A.; MARQUEZ, Manlio F.; POTPARA, Tatjana; POZZER, Domingo Luis; RUSKIN, Jeremy N.; SAVELIEVA, Irina; TEO, Wee Siong; TSE, Hung-Fat; VERMA, Atul; ZHANG, Shu; CHUNG, Mina K.
- Diretriz Brasileira de Dispositivos Cardiacos Eletronicos Implantaveis-2023(2023) TEIXEIRA, Ricardo Alkmim; FAGUNDES, Alexsandro Alves; JR, Jose Mario Baggio; OLIVEIRA, Julio Cesar de; MEDEIROS, Paulo de Tarso Jorge; VALDIGEM, Bruno Pereira; TENO, Luiz Antonio Castilho; SILVA, Rodrigo Tavares; MELO, Celso Salgado de; ELIAS NETO, Jorge; JR, Antonio Vitor Moraes; PEDROSA, Anisio Alexandre Andrade; PORTO, Fernando Mello; JR, Helio Lima de Brito; SOUZA, Thiago Goncalves Schroder e; MATEOS, Jose Carlos Pachon; MORAES, Luis Gustavo Belo de; FORNO, Alexander Romeno Janner Dal; D'AVILA, Andre Luiz Buchele; CAVACO, Diogo Alberto de Magalhaes; KUNIYOSHI, Ricardo Ryoshim; PIMENTEL, Mauricio; CAMANHO, Luiz Eduardo Montenegro; SAAD, Eduardo Benchimol; ZIMERMAN, Leandro Ioschpe; OLIVEIRA, Eduardo Bartholomay; SCANAVACCA, Mauricio Ibrahim; MARTINELLI FILHO, Martino; LIMA, Carlos Eduardo Batista de; PEIXOTO, Giselle de Lima; DARRIEUX, Francisco Carlos da Costa; DUARTE, Jussara de Oliveira Pinheiro; GALVAO FILHO, Silas dos Santos; COSTA, Eduardo Rodrigues Bento; MATEO, Enrique Indalecio Pachon; MELO, Sissy Lara De; RODRIGUES, Thiago da Rocha; ROCHA, Eduardo Arrais; HACHUL, Denise Tessariol; LORGA FILHO, Adalberto Menezes; NISHIOKA, Silvana Angelina D'Orio; GADELHA, Eduardo Barreto; COSTA, Roberto; ANDRADE, Veridiana Silva de; TORRES, Gustavo Gomes; OLIVEIRA NETO, Nestor Rodrigues de; LUCCHESE, Fernando Antonio; MURAD, Henrique; WANDERLEY NETO, Jose; BROFMAN, Paulo Roberto Slud; ALMEIDA, Rui M. S.; LEAL, Joao Carlos Ferreira
- Incor Residency Program in Adult Cardiology in 2022: 40 Years Preparing Cardiologists for the Demands in Brazil(2022) LOTTENBERG, Marcos Pita; BICHUETTE, Luciana Dornfeld; BORTOLOTTO, Luiz Aparecido; GOWDAK, Luis Henrique Wolff; DARRIEUX, Francisco Carlos da Costa; BINOTTO, Maria Angelica; KALIL FILHO, Roberto; CARAMELLI, BrunoBackground: Considering demographic data related to the cardiologist's fields of work in Brazil, the administrative board of the InCor medical residency program decided for an update of its curriculum content, to adapt the educational process to the cardiologist's work reality. Objective: This article aimed to describe the recent updates applied to the InCor medical residency program. Methods: In the article, we described the recent updates on the InCor residency program, and compared the current curriculum track with the previous one. We also presented the rationale for these changes, based on the literature on the participation of cardiologists in the labor market. Results: There was a reduction in the working hours of residents in training in the intensive care unit, and an increase in the outpatient activities of primary and secondary prevention. Also, the didactic content was reformulated and became organized by the corresponding division. Conclusion: The update of the curriculum track of the InCor medical residency program was required in order to adapt it to the Brazilian labor market. The commission in charge of this update is aware that this is a dynamic process that may need changes over time.
- Evaluation of the Long-Term Impact on Quality After the End of Pharmacist-Driven Warfarin Therapy Management in Patients With Poor Quality of Anticoagulation Therapy(2020) MARCATTO, Leiliane Rodrigues; SACILOTTO, Luciana; TAVARES, Leticia Camargo; SOUZA, Debora Stephanie Pereira; OLIVETTI, Natalia; STRUNZ, Celia Maria Cassaro; DARRIEUX, Francisco Carlos Costa; SCANAVACCA, Mauricio Ibrahim; KRIEGER, Jose Eduardo; PEREIRA, Alexandre Costa; SANTOS, Paulo Caleb Junior LimaBackground Warfarin is the most common oral anticoagulant drug, especially in low-income and emerging countries, because of the high cost of direct oral anticoagulant (DOACs), or when warfarin is the only proven therapy (mechanical prosthetic valve and kidney dysfunction). The quality of warfarin therapy is directly associated with dose management. Evidence shows that pharmaceutical care achieves a better quality of therapy with warfarin. However, there are no studies showing this intervention in a specific patient group with poor quality of anticoagulation in a long period after the end of the follow-up by a pharmacist. Thus, the aim of this study was to evaluate whether the quality of warfarin therapy driven by a pharmacist remains stable in the long term after the end of follow up with a pharmacist, in AF patients with poor quality of anticoagulation. Methods This is a prospective study, which evaluated about 2,620 patients and selected 262 patients with AF and poor quality of anticoagulation therapy with warfarin (TTR<50% - based on the last three values of international normalized ratio). Pharmacist-driven therapy management was performed up to 12 weeks. Data from patients were evaluated 1 year after the end of the follow-up with pharmacist. Results Comparison between mean TTR after 12 weeks of pharmaceutical care (54.1%) and mean TTR one year after the end of the pharmaceutical care (56.5%; p=0.081) did not achieve statistical difference, demonstrating that the increment of quality due to intervention of 12 weeks was maintained for 1 year after intervention. Conclusion The long-term impact of pharmaceutical care was beneficial for patients with AF and poor quality of warfarin anticoagulation. This design might be an important strategy to treat a subgroup of patients without proven effectiveness of warfarin.
- Effect of Occurrence of Lamin A/C (LMNA) Genetic Variants in a Cohort of 101 Consecutive Apparent ""Lone AF"" Patients: Results and Insights(2022) PESSENTE, Gabrielle D'Arezzo; SACILOTTO, Luciana; CALIL, Zaine Oliveira; OLIVETTI, Natalia Quintella Sangiorgi; WULKAN, Fanny; OLIVEIRA, Theo Gremen Mimary de; PEDROSA, Anisio Alexandre Andrade; WU, Tan Chen; HACHUL, Denise Tessariol; SCANAVACCA, Mauricio Ibrahim; KRIEGER, Jose Eduardo; DARRIEUX, Francisco Carlos da Costa; PEREIRA, Alexandre da CostaObjectiveMutations in the Lamin A/C (LMNA) gene are commonly associated with cardiac manifestations, such as dilated cardiomyopathy (DCM) and conduction system disease. However, the overall spectrum and penetrance of rare LMNA variants are unknown. The present study described the presence of LMNA variants in patients with ""lone atrial fibrillation (AF)"" as their sole clinical presentation. MethodsOne-hundred and one consecutive patients with ""lone AF"" criteria were initially screened by genetic testing. Genetic variants were classified according to the American College of Genetic and Genomic criteria. All subjects were evaluated through clinical and familial history, ECG, 24-h Holter monitoring, echocardiogram, cardiac magnetic resonance, treatment response, and the present relatives of LMNA carriers. In addition, whole-exome data from 49,960 UK Biobank (UKB) participants were analyzed to describe the overall penetrance of rare LMNA missense and loss of function (LOF) variants. ResultsThree missense variants in LMNA were identified in probands with AF as their first and unique clinical manifestation. Other five first-degree relatives, after the screening, also presented LMNA gene variants. Among 49,960 analyzed UKB participants, 331 carried rare LMNA missense or LOF variant. Participants who carried a rare LMNA variant were significantly associated with higher odds of arrhythmic events and of an abnormal ECG in the per-protocol ECG exam (p = 0.03 and p = 0.05, respectively). ConclusionAlthough a rare occurrence, our findings emphasize the possibility of an initial presentation of apparently ""lone AF"" in LMNA gene variant carriers.
- Pharmaceutical Care Increases Time in Therapeutic Range of Patients With Poor Quality of Anticoagulation With Warfarin(2018) MARCATTO, Leiliane Rodrigues; SACILOTTO, Luciana; TAVARES, Leticia Camargo; FACIN, Mirella; OLIVETTI, Natalia; STRUNZ, Celia Maria Cassaro; DARRIEUX, Francisco Carlos Costa; SCANAVACCA, Mauricio Ibrahim; KRIEGER, Jose Eduardo; PEREIRA, Alexandre Costa; SANTOS, Paulo Caleb Junior LimaThromboembolic events are associated with high mortality and morbidity indexes. In this context, warfarin is the most widely prescribed oral anticoagulant agent for preventing and treating these events. This medication has a narrow therapeutic range and, consequently, patients usually have difficulty in achieving and maintaining stable target therapeutics. Some studies on the literature about oral anticoagulant management showed that pharmacists could improve the efficiency of anticoagulant therapy. However, the majority of these studies included general patients retrospectively. The aim of this study was to prospectively evaluate a pharmacist's warfarin management in patients with poor quality of anticoagulation therapy (Time in the Therapeutic Range-TTR < 50%). We included 268 patients with atrial fibrillation (AF) and without stable dose of warfarin (TTR < 50%, based on the last three values of International Normalized Ratio-INR). We followed them up for 12 weeks, INR values were evaluated and, when necessary, the dose adjustments were performed. During the first four visits, patient's INR was measured every 7 days. Then, if INR was within the target therapeutic range (INR: 2-3), the patient was asked to return in 30 days. However, if INR was out the therapeutic target, the patient was asked to return in 7 days. Adherence evaluation was measured through questionnaires and by counting the pills taken. Comparison between basal TTR (which was calculated based on the three last INR values before prospective phase) and TTR of 4 weeks (calculated by considering the INR tests from visits 0 to 4, in the prospective phase of the study) and basal TTR and TTR of 12 weeks (calculated based on the INR tests from visits 0 to 12, in the prospective phase of the study) revealed significant statistical differences (0.144 +/- 0.010 vs. 0.382 +/- 0.016; and 0.144 +/- 0.010 vs. 0.543 +/- 0.014, p < 0.001, respectively). We also observed that the mean TTR of 1 year before (retrospective phase) was lower than TTR value after 12 weeks of pharmacist-driven treatment (prospective phase) (0.320 +/- 0.015; 0.540 +/- 0.015, p < 0.001). In conclusion, pharmaceutical care was able to improve TTR values in patients with AF and poor quality of anticoagulation with warfarin.
- Evaluation of a new treadmill exercise protocol to unmask type 1 Brugada electrocardiographic pattern: can we improve diagnostic yield?(2023) PICHARA, Nemer L.; SACILOTTO, Luciana; I, Mauricio Scanavacca; CARDOSO, Acacio Fernandes; SOARES, Beatriz Moreira Ayub Ferreira; FALCOCHIO, Paola P. P. N. F.; FALCAO, Andrea M. G.; OLIVETTI, Natalia; DARRIEUX, Francisco Carlos da Costa; CHALELA, William A.Aims High precordial leads (HPL) on the resting electrocardiogram (ECG) are widely used to improve diagnostic detection of type 1 Brugada ECG pattern (Br1ECGp). A parasympathetic activation marks the initial recovery phase of treadmill stress testing (TET), and this can be useful for detecting the typical ECG pattern. Our study aimed to evaluate the role of a new HPL-treadmill exercise testing (TET) protocol in detecting Br1ECGp fluctuation compared to resting HPL-ECG. Methods and results 74 out of 163 patients of a Brugada syndrome (BrS) Brazilian cohort (GenBra Registry) underwent exercise testing with HPL-TET protocol. Precordial leads were displayed in strategic positions in the right and left parasternal spaces. The step-by-step analysis included ECG classification (as presence or absence of Br1ECGp) in standard vs. HPL leads placement in the following sequences: resting phase, maximal exercise, and the passive recovery phase (including 'quick lay down'). For heart rate recovery (HRR) measurements and comparisons, a Student's t-test was applied. McNemar tests compared the detection of Br1ECGp. The significance level was defined as P < 0.05. Fifty-seven patients (57/74; 77%) were male, the mean age was 49.0 & PLUSMN; 14, 78.4% had spontaneous BrS, and the mean Shanghai score was 4.5. The HPL-TET protocol increased Br1ECGp detection by 32.4% against resting HPL-ECG (52.7% vs. 20.3%, P = 0.001) alone. Conclusion Stress testing using HPL with the passive recovery phase in the supine position offers an opportunity to unmask the type 1 Br1ECGp, which could increase the diagnostic yield in this population.
- European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases(2022) WILDE, Arthur A. M.; SEMSARIAN, Christopher; MARQUEZ, Manlio F.; SHAMLOO, Alireza Sepehri; ACKERMAN, Michael J.; ASHLEY, Euan A.; EDUARDO, Back Sternick; BARAJAS-MARTINEZ, Hector; BEHR, Elijah R.; BEZZINA, Connie R.; BRECKPOT, Jeroen; CHARRON, Philippe; CHOCKALINGAM, Priya; CROTTI, Lia; GOLLOB, Michael H.; LUBITZ, Steven; MAKITA, Naomasa; OHNO, Seiko; ORTIZ-GENGA, Martin; SACILOTTO, Luciana; SCHULZE-BAHR, Eric; SHIMIZU, Wataru; SOTOODEHNIA, Nona; TADROS, Rafik; WARE, James S.; WINLAW, David S.; KAUFMAN, Elizabeth S.; AIBA, Takeshi; BOLLMANN, Andreas; CHOI, Jong-Il; DALAL, Aarti; DARRIEUX, Francisco; GIUDICESSI, John; GUERCHICOFF, Mariana; HONG, Kui; KRAHN, Andrew D.; INTYRE, Ciorsti Mac; MACKALL, Judith A.; MONT, Lluis; NAPOLITANO, Carlo; JUAN, Pablo Ochoa; PEICHL, Petr; PEREIRA, Alexandre C.; SCHWARTZ, Peter J.; SKINNER, Jon; STELLBRINK, Christoph; TFELT-HANSEN, Jacob; DENEKE, Thomas
- Sinus Node Artery Occlusion During Cardiac Denervation Procedures(2022) SCANAVACCA, M.; RIVAROLA, E. W. R.; TORRES, R. V. A.; HARDY, C.; WU, T. C.; DARRIEUX, F.; PISANI, C.; HACHUL, D.Cardioneural ablation is a novel treatment for functional bradycardia. However, the risk of acute complications is still unknown. The aim of this case report is to describe acute occlusion of the sinus node artery after cardiac denervation procedures in 2 patients and to encourage measures to prevent it, such as evaluating the aortic angulation in older patients before the procedure and by monitoring signs of sinus failure during ablation in patients with electroanatomical maps showing a constricted aspect of the right atrium. (Level of Difficulty: Advanced.) © 2022 The Authors
- Long-Term Outcome of Cardiac Denervation Procedures The Anatomically Guided Septal Approach(2023) RIVAROLA, Esteban W. R.; HACHUL, Denise; WU, Tan Chen; PISANI, Cristiano; SCARIOTI, Vinicius D.; HARDY, Carina; DARRIEUX, Francisco; SCANAVACCA, MauricioBACKGROUND Functional bradycardia is a challenging condition that affects a healthy population. Ganglionated plexus ablation has emerged as a therapeutic alternative to avoid a pacemaker. OBJECTIVES The purpose of this study is to evaluate long-term effects of anatomically guided cardiac denervation. METHODS This is a prospective longitudinal study that included 36 patients with symptomatic functional bradycardia. Electroanatomic reconstruction of both atria was carried out, and the main septal ganglionated plexi were anatomically located and targeted.RESULTS Ablation endpoints were: 1) heart rate increment; 2) Wenckebach cycle length shortening; and 3) atrio-Hisian (AH) interval shortening. A sinus node denervation was obtained in all patients with an increment of 21.6% in the mean heart rate. All patients presented a negative atropine test after ablation. Twenty-eight (77.7%) patients presented immediate sings of atrioventricular node denervation, with a shortening of 15.6% of mean Wenckebach cycle length and 15.9% of the mean AH interval. All heart rate variability parameters showed a significant reduction after 12 months, enduring after 18 months. Thirty (83.3%) patients remained free of events after a mean follow-up of 52.1 & PLUSMN; 35.2 months. One patient (2.77%) presented acute sinus node artery occlusion during ablation with persistent sinus dysfunction and had a pacemaker implantation; 3 (8.3%) other patients evolved with sinus tachycardia, and 4 (11.1%) patients presented syncope recurrence during follow-up, 3 (8.3%) of them requiring a pacemaker implantation. No other tachyarrhythmia was observed.CONCLUSIONS The anatomically guided septal approach is an effective technique for syncope prevention, promoting long-lasting autonomic changes. No significant proarrhythmia effect has been observed during the long-term follow-up. (J Am Coll Cardiol EP 2023;9:1344-1353) & COPY; 2023 by the American College of Cardiology Foundation.